Chemo plus immunotherapy before surgery for colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colon cancer that has not been treated before and is at a stage where it has spread to nearby lymph nodes but not to distant organs.
- Your tumor has a specific genetic makeup: MSS (microsatellite stable) and a RAS mutation.
- You are between 18 and 75 years old and in good general health (able to walk and take care of yourself).
- You have not had any prior cancer treatment like chemotherapy, radiation, or immunotherapy.
- You do not have active infections, autoimmune diseases, or other serious health problems that could interfere with the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (pembrolizumab and porustobart) given before surgery for colon cancer that can be removed. The goal is to see if this treatment can help shrink the tumor and improve outcomes.
This trial tests whether giving chemotherapy before surgery can improve outcomes for patients with colon cancer that has not spread to other parts of the body. The treatment aims to shrink the tumor and reduce the chance of the cancer coming back.
This trial tests whether giving radiation therapy along with standard chemotherapy before surgery can help shrink advanced colon cancer that has grown through the bowel wall but hasn't spread to other organs. It is for a specific type of colon cancer called pMMR/MSS.
This Phase 2 trial studies giving chemotherapy plus immune therapy before surgery for certain colon cancers that do not have mismatch repair defects (MSS/pMMR). The goal is to shrink and control the tumor and improve outcomes compared with standard approaches.
This trial tests a combination of chemotherapy (CapeOX), a targeted drug (bevacizumab), and an immunotherapy (anti-PD1) given before surgery for colorectal cancer that has come back locally (in the same area). The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a new combination of two chemotherapy drugs (CAPOX) plus an immunotherapy drug (tislelizumab) before surgery for high-risk colon cancer that has not spread. It aims to see if adding tislelizumab helps shrink the tumor and lower the chance of the cancer coming back.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.